Ratings by Mizuho (Mara Goldstein)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/31/2026 | Autolus Therapeutics plc | AUTL | Maintain | Outperform (N/A) |
|
Details | ||
| 3/27/2026 | Autolus Therapeutics plc | AUTL | Maintain | Outperform (N/A) |
|
Details | ||
| 3/24/2026 | Fate Therapeutics | FATE | Maintain | Outperform (N/A) |
|
Details | ||
| 12/8/2025 | Incyte | INCY | Upgrade | Outperform (Neutral) |
100.46 (108.91) |
8.41% | Details | |
| 11/4/2025 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 11/4/2025 | Arcus Biosciences | RCUS | Maintain | Outperform (N/A) |
|
Details | ||
| 8/18/2025 | Arcus Biosciences | RCUS | Maintain | Outperform (N/A) |
|
Details | ||
| 8/5/2025 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 5/19/2025 | Kura Oncology | KURA | Maintain | Outperform (N/A) |
|
Details | ||
| 5/12/2025 | Iovanace Biotherapeutics | IOVA | Maintain | Outperform (N/A) |
|
Details | ||
| 5/5/2025 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 3/20/2025 | Autolus Therapeutics plc | AUTL | Maintain | Outperform (N/A) |
|
Details | ||
| 3/17/2025 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 1/31/2024 | Kura Oncology | KURA | Maintain | Outperform (N/A) |
|
Details | ||
| 1/30/2024 | Arcus Biosciences | RCUS | Maintain | Outperform (N/A) |
|
Details | ||
| 1/22/2024 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 1/16/2024 | eFFECTOR Therapeutics, Inc. | EFTR | Maintain | Outperform (N/A) |
|
Details | ||
| 1/5/2024 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 12/22/2023 | Syndax Pharmaceuticals | SNDX | New Coverage | Outperform (N/A) |
20.15 (20.23) |
0.4% | Details | |
| 12/22/2023 | Kura Oncology | KURA | New Coverage | Outperform (N/A) |
12.57 (10.63) |
-15.43% | Details | |
| 12/14/2023 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 12/13/2023 | IN8bio Inc. | INAB | Maintain | Outperform (N/A) |
|
Details | ||
| 11/29/2023 | Erasca Inc | ERAS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/20/2023 | Leap Therapeutics | LPTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/20/2023 | Fate Therapeutics | FATE | Maintain | Outperform (N/A) |
|
Details | ||
| 11/8/2023 | Nektar Therapeutics | NKTR | Maintain | Neutral (N/A) |
|
Details | ||
| 8/23/2023 | Arcus Biosciences | RCUS | Maintain | Outperform (N/A) |
|
Details | ||
| 6/15/2023 | Verastem | VSTM | Upgrade | (Neutral) |
9.53 (3.90) |
-59.08% | Details | |
| 6/6/2023 | Erasca Inc | ERAS | Maintain | Outperform (N/A) |
|
Details | ||
| 5/12/2023 | TCR2 Therapeutics | TCRR | Maintain | Neutral (N/A) |
|
Details | ||
| 5/9/2023 | Neoleukin Therapeutics | NLTX | Maintain | Neutral (N/A) |
|
Details | ||
| 5/3/2023 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 4/19/2023 | Immuneering Corporation | IMRX | Upgrade | Outperform (Neutral) |
12.19 (4.55) |
-62.67% | Details | |
| 3/30/2023 | Immuneering Corporation | IMRX | New Coverage | Neutral (N/A) |
9.38 (4.55) |
-51.49% | Details | |
| 3/30/2023 | Erasca Inc | ERAS | New Coverage | Outperform (N/A) |
2.74 (14.72) |
437.23% | Details | |
| 3/30/2023 | Verastem | VSTM | New Coverage | Neutral (N/A) |
0.42 (3.90) |
828.57% | Details | |
| 3/28/2023 | CytomX Therapeutics | CTMX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/24/2023 | TCR2 Therapeutics | TCRR | Downgrade | Neutral (Outperform) |
1.47 (1.48) |
0.68% | Details | |
| 3/17/2023 | Leap Therapeutics | LPTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/8/2023 | Autolus Therapeutics plc | AUTL | Maintain | Outperform (N/A) |
|
Details | ||
| 1/6/2023 | Fate Therapeutics | FATE | Maintain | Outperform (N/A) |
|
Details | ||
| 12/14/2022 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 11/15/2022 | Neoleukin Therapeutics | NLTX | Downgrade | Neutral (Outperform) |
0.54 (3.49) |
546.3% | Details | |
| 11/9/2022 | Adaptimmune Therapeutics plc | ADAP | Upgrade | Outperform (Neutral) |
1.66 (0.05) |
-96.99% | Details | |
| 8/12/2022 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 7/7/2022 | CytomX Therapeutics | CTMX | Downgrade | Neutral (Outperform) |
1.94 (3.36) |
73.2% | Details | |
| 6/28/2022 | Fate Therapeutics | FATE | Maintain | Outperform (Outperform) |
|
Details | ||
| 6/28/2022 | Fate Therapeutics | FATE | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2022 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 5/3/2022 | Incyte | INCY | Maintain | Outperform (Outperform) |
|
Details | ||
| 4/26/2022 | Nektar Therapeutics | NKTR | Maintain | Neutral (Neutral) |
|
Details | ||
| 4/18/2022 | Nektar Therapeutics | NKTR | Maintain | Outperform (N/A) |
|
Details | ||
| 4/14/2022 | Xencor, Inc. | XNCR | Maintain | Outperform (Outperform) |
|
Details | ||
| 4/11/2022 | TCR2 Therapeutics | TCRR | Maintain | Outperform (Outperform) |
|
Details | ||
| 4/11/2022 | Arcus Biosciences | RCUS | Maintain | Outperform (Outperform) |
|
Details | ||
| 4/11/2022 | IN8bio Inc. | INAB | Maintain | Outperform (Outperform) |
|
Details | ||
| 4/7/2022 | eFFECTOR Therapeutics, Inc. | EFTR | Maintain | Outperform (Outperform) |
|
Details | ||
| 4/4/2022 | eFFECTOR Therapeutics, Inc. | EFTR | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/31/2022 | Akebia Therapeutics | AKBA | Downgrade | Neutral (Outperform) |
0.83 (1.07) |
28.92% | Details | |
| 3/22/2022 | TCR2 Therapeutics | TCRR | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/17/2022 | eFFECTOR Therapeutics, Inc. | EFTR | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/15/2022 | Nektar Therapeutics | NKTR | Downgrade | Neutral (Outperform) |
10.63 (64.65) |
508.18% | Details | |
| 3/14/2022 | Nektar Therapeutics | NKTR | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/10/2022 | Autolus Therapeutics plc | AUTL | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/1/2022 | Fate Therapeutics | FATE | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/24/2022 | Xencor, Inc. | XNCR | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/24/2022 | Arcus Biosciences | RCUS | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/8/2022 | Incyte | INCY | Maintain | Neutral (Neutral) |
|
Details | ||
| 2/3/2022 | Merck | MRK | Maintain | Outperform (Outperform) |
|
Details | ||
| 1/20/2022 | Merck | MRK | Maintain | Outperform (Outperform) |
|
Details | ||
| 1/18/2022 | Incyte | INCY | Maintain | Neutral (Neutral) |
|
Details | ||
| 12/13/2021 | Fate Therapeutics | FATE | Maintain | Outperform (N/A) |
|
Details | ||
| 12/2/2021 | Nektar Therapeutics | NKTR | New Coverage | Outperform (N/A) |
11.26 (64.65) |
474.16% | Details | |
| 12/2/2021 | CASI Pharmaceuticals | CASI | New Coverage | Outperform (N/A) |
0.90 (0.21) |
-76.67% | Details | |
| 12/2/2021 | Akebia Therapeutics | AKBA | New Coverage | Outperform (N/A) |
2.71 (1.07) |
-60.52% | Details | |
| 11/18/2021 | Arcus Biosciences | RCUS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/9/2021 | Arcus Biosciences | RCUS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/8/2021 | AUTL | AUTL | Maintain | Outperform (N/A) |
|
Details | ||
| 11/5/2021 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 11/2/2021 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 10/22/2021 | Leap Therapeutics | LPTX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/21/2021 | TCR2 Therapeutics | TCRR | Maintain | Outperform (N/A) |
|
Details | ||
| 10/4/2021 | eFFECTOR Therapeutics, Inc. | EFTR | New Coverage | (N/A) |
14.05 (0.18) |
-98.72% | Details | |
| 10/4/2021 | Leap Therapeutics | LPTX | New Coverage | (N/A) |
4.01 (2.06) |
-48.63% | Details | |
| 9/14/2021 | Kadmon Holdings | KDMN | Downgrade | Neutral (Outperform) |
9.09 (9.50) |
4.51% | Details | |
| 9/1/2021 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 8/24/2021 | IN8bio Inc. | INAB | New Coverage | Outperform (N/A) |
8.09 (1.51) |
-81.33% | Details | |
| 8/3/2021 | Corvus Pharmaceuticals | CRVS | Maintain | Neutral (N/A) |
|
Details | ||
| 7/20/2021 | Arcus Biosciences | RCUS | Maintain | Outperform (N/A) |
|
Details | ||
| 6/23/2021 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 6/22/2021 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 6/22/2021 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 5/19/2021 | Iovanace Biotherapeutics | IOVA | Maintain | Outperform (N/A) |
|
Details | ||
| 4/8/2021 | CytomX Therapeutics | CTMX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/11/2021 | TCR2 Therapeutics | TCRR | Maintain | Outperform (N/A) |
|
Details | ||
| 2/25/2021 | Arcus Biosciences | RCUS | Maintain | Outperform (N/A) |
|
Details | ||
| 2/25/2021 | Fate Therapeutics | FATE | Maintain | Outperform (N/A) |
|
Details | ||
| 2/10/2021 | Corvus Pharmaceuticals | CRVS | Downgrade | Neutral (Outperform) |
4.28 (12.95) |
202.57% | Details | |
| 1/19/2021 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 1/7/2021 | AUTL | AUTL | Maintain | Outperform (N/A) |
|
Details | ||
| 12/14/2020 | TCR2 Therapeutics | TCRR | Maintain | Outperform (N/A) |
|
Details | ||
| 12/8/2020 | Fate Therapeutics | FATE | Maintain | Outperform (N/A) |
|
Details | ||
| 11/10/2020 | Kadmon Holdings | KDMN | New Coverage | Outperform (N/A) |
3.36 (9.50) |
182.74% | Details | |
| 10/12/2020 | Iovanace Biotherapeutics | IOVA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/21/2020 | TCR2 Therapeutics | TCRR | New Coverage | Outperform (N/A) |
19.82 (1.48) |
-92.53% | Details | |
| 8/5/2020 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 7/8/2020 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 7/6/2020 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 6/23/2020 | Merck | MRK | Maintain | Outperform (Outperform) |
|
Details | ||
| 6/19/2020 | Autolus Therapeutics | AUTL | Maintain | Outperform (N/A) |
|
Details | ||
| 6/18/2020 | Neoleukin Therapeutics | NLTX | New Coverage | Outperform (N/A) |
13.29 (3.49) |
-73.74% | Details | |
| 5/29/2020 | Adaptimmune Therapeutics plc | ADAP | Maintain | Neutral (N/A) |
|
Details | ||
| 5/14/2020 | Arcus Biosciences | RCUS | Maintain | Outperform (N/A) |
|
Details | ||
| 4/22/2020 | AUTL | AUTL | New Coverage | Outperform () |
9.20 (1.61) |
-82.5% | Details | |
| 4/22/2020 | Adaptimmune Therapeutics plc | ADAP | New Coverage | Neutral (N/A) |
3.58 (0.05) |
-98.6% | Details | |
| 4/22/2020 | Iovanace Biotherapeutics | IOVA | New Coverage | Outperform (N/A) |
36.66 (4.35) |
-88.13% | Details | |
| 4/7/2020 | Incyte | INCY | Maintain | Neutral (Neutral) |
|
Details | ||
| 3/4/2020 | Forty Seven Inc. | FTSV | Downgrade | Neutral (Outperform) |
93.91 (95.51) |
1.7% | Details | |
| 2/26/2020 | Fate Therapeutics | FATE | Maintain | Outperform (N/A) |
|
Details | ||
| 2/26/2020 | Fate Therapeutics | FATE | Maintain | Outperform (N/A) |
|
Details | ||
| 2/12/2020 | Forty Seven Inc. | FTSV | Maintain | Outperform (N/A) |
|
Details | ||
| 1/3/2020 | Incyte | INCY | Downgrade | Neutral (Outperform) |
87.32 (100.46) |
15.05% | Details | |
| 12/30/2019 | Fate Therapeutics | FATE | Maintain | Outperform (N/A) |
|
Details | ||
| 12/10/2019 | Forty Seven Inc. | FTSV | Maintain | Outperform (N/A) |
|
Details | ||
| 12/9/2019 | Fate Therapeutics | FATE | Maintain | Outperform (N/A) |
|
Details | ||
| 11/6/2019 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 10/30/2019 | Incyte | INCY | Maintain | Outperform (N/A) |
|
Details | ||
| 10/30/2019 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 10/28/2019 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 10/18/2019 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 10/14/2019 | Incyte | INCY | Maintain | Outperform (Outperform) |
|
Details | ||
| 10/3/2019 | Incyte | INCY | New Coverage | Outperform (N/A) |
73.96 (108.91) |
47.26% | Details | |
| 9/27/2019 | Arcus Biosciences | RCUS | New Coverage | Outperform (N/A) |
8.98 (28.92) |
222.05% | Details | |
| 9/12/2019 | Fiserv | FTSV | New Coverage | Outperform (N/A) |
103.69 (95.51) |
-7.89% | Details | |
| 9/12/2019 | Corvus Pharmaceuticals | CRVS | New Coverage | Outperform (N/A) |
4.19 (12.95) |
209.07% | Details | |
| 7/3/2019 | Merck | MRK | New Coverage | Outperform (N/A) |
84.75 (121.30) |
43.13% | Details | |
| 6/13/2019 | CytomX Therapeutics | CTMX | New Coverage | Outperform (N/A) |
9.99 (3.36) |
-66.37% | Details | |
| 6/13/2019 | Fate Therapeutics | FATE | New Coverage | Outperform (N/A) |
16.02 (2.08) |
-87.02% | Details | |
| 6/13/2019 | Xencor, Inc. | XNCR | New Coverage | Outperform (N/A) |
31.38 (14.42) |
-54.05% | Details |
